microdosing glp-1 perimenopause Weight Loss in Menopause: How HRT Amplifies Results I know so many women

Zhang QY, et al

JNCI Cancer Spectr

Ascendis Pharma A/S granted Novo Nordisk A/S exclusive global rights to its TransCon technology for the development, manufacturing, and commercialisation of Novo Nordisk products aimed at metabolic diseases, including obesity and type 2 diabetes, along with select cardiovascular applications

19, 2026, 9:48 PM UTC The First Circuit rejected a lawsuit accusing Cigna Health & Life Insurance Co

These findings emphasize that targeted antagonism of NMDA receptor signalling lowers body weight independently of MC4R, indicating that this preclinical drug candidate might not only be effective in treating polygenic obesity but also holds potential as an effective weight loss strategy for patients with loss-of-function mutations in MC4R , the most common form of monogenic obesity 32